Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BURROUGHS WELLCOME's DETAILS ON ZOVIRAX PATIENT EDUCATION PROGRAM REQUESTED

This article was originally published in The Tan Sheet

Executive Summary

BURROUGHS WELLCOME's DETAILS ON ZOVIRAX PATIENT EDUCATION PROGRAM REQUESTED for the upcoming joint meeting of FDA's Antiviral Drugs and Nonprescription Drugs Advisory Committees by OTC committee member Alan Sinaiko, MD, University of Minnesota. At a May 19 joint session of the committees, Sinaiko asked that Burroughs Wellcome present "their plan for [consumer] education" on OTC Zovirax (acyclovir) on July 28, the date tentatively set by FDA for the committees to review the Rx-to-OTC switch of the drug.

Topics

UsernamePublicRestriction

Register

PS082805

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel